Janux Therapeutics
The Clinical Biomarker Lead at Janux Therapeutics will join the Translational group to develop and execute biomarker analysis plans and data analytics strategy for early-stage oncology programs. The role focuses on deriving critical insights from preclinical, translational, and clinical trial data to inform strategic decision-making across the portfolio.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2017
Janux Therapeutics is a biotechnology company developing precision‑engineered T cell immunotherapies. They design novel therapeutics that selectively modulate T cells to treat cancer and autoimmune diseases while minimizing systemic safety issues. Their approach focuses on targeted modulation of immune responses to improve efficacy and reduce toxicity. Janux aims to translate selective T‑cell control into safer, more effective immunotherapies.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Janux Therapeutics.
Janux Therapeutics didn’t post a salary, so this is our estimate from similar listings.
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
1 month ago
Biomarker Strategy & Scientific Leadership
Scholar Rock
Clinical Bioanalysis Subject Matter Expert
Scholar Rock
Senior Director, Biomarker Development, Strategy, and Operations
Zenas BioPharma
Principal Scientist, Translational Bioanalysis and Biomarkers
Nucleome
Senior Director, Translational and Biomarker Lead
Merck & Co., Inc.
Senior Director, Translational and Biomarker Lead
Merck & Co., Inc.